MIAMI, March 31, 2015 /PRNewswire/ -- Biorasi, a full-service CRO powered by TALOS™, today announced a strategic partnership with Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences. Offering therapeutic expertise in a number of areas, the global CRO has deployed Medidata's electronic data capture (EDC), management and reporting system, Medidata Rave®, to support Biorasi's Phase I through IV global clinical trial business.
"Biorasi's adoption of Rave has greatly benefited our clinical trials process. The dynamic, easy-to-use technology offers our platform TALOS™ the power to do more compared to other EDC systems," says Dr Boris Reznik, Chairman of Biorasi. "We plan to double in growth this year due to the rising demand of Biosimilars and Interchangeables studies from leading pharmaceutical companies around the world. Utilizing enterprise suite technology allows us to fully leverage our core competency of trial optimization."
As a Medidata Services Partner, Biorasi and its customers gain the advantages of a multi-dimensional, full suite of Medidata products to optimize clinical trial operations and save costs, reduce timelines and mitigate risk. In addition to Rave, the CRO is currently working towards gaining accreditations in Medidata's electronic patient-reported outcome (ePRO) solution for patient-centric data capture (Medidata Patient Cloud®), and Medidata's medical coding solution (Medidata Coder®).
"We are very pleased to have Biorasi join the Medidata Partner Ecosystem and look forward to growing and innovating jointly in this very exciting time of emerging Biosimilars development," says Medidata SVP of Global Partner Business, Pat Bernard. "Medidata can support Biorasi's mission of developing and implementing groundbreaking methods of optimizing clinical research with the scalable, flexible and easily configurable nature of the Medidata Clinical Cloud® and help Biorasi in its innovative efforts to deliver successful new treatments for time-critical indications."
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.